NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from ... progressive genetic ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a ...

On the other hand, Merck Foundation is also partnering the donation under ... “Adolescence can be a slippery and lonely road especially when you do not have supportive people to talk to, so it is nice ...

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

A giant letter "L" was installed in the Lindsay Heights neighborhood on Tuesday, Nov. 12. It's one of six WaterMarkers in the city of Milwaukee. WaterMarkers show an illuminated blue letter, chosen b ...

Everyone’s favourite elephant is back in town. Ditching the denim, Hipgnosis has put on a suit, brushed its hair and sat down ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...